A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 31 Oct 2023
At a glance
- Drugs SPYK 04 (Primary)
- Indications Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 25 Oct 2023 Planned End Date changed from 31 Mar 2024 to 30 Sep 2024.
- 25 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.
- 27 Sep 2020 Status changed from not yet recruiting to recruiting.